HER-3 Knocking Down Induces G2/M Arrest in Gastric Cancer Cells

Overview

Journal Avicenna J Med Biotechnol

Specialty Biomedical Engineering

Date 2018 Dec 18

PMID 30555655

Citations 1

Authors

Ehsan Mokhtari

Hesamodin Mokhtari

Elham Moslemi

Affiliations

Soon will be listed here.

Abstract

Background: The Human Epidermal growth factor Receptor-3 (HER-3) is a member of ErbB receptor family and has deficient kinase activity. HER-3 should heterodimerize with other members of ErbB receptor family, especially with HER-2, to transduce downstream signaling pathways. HER-3 co-expresses with other ErbB receptors in different cancers and overexpresses while the oncogenic signaling pathways such as Jak/Stat, MAPK, and PI3K/Akt are activated and promoted. Here, the expression level of HER-3 was evaluated in Iranian gastric adenocarcinoma's patients and the effects of HER-3 knocking down was investigated on cell cycle and cell viability of human gastric adenocarcinoma cell line of MKN45.

Methods: In this study, 38 paraffin-embedded surgical adenocarcinoma specimens and their marginal non-tumor tissue samples were collected. Total RNAs were extracted and cDNAs were synthesized. Finally, the expression level of HER-3 was evaluated by real time PCR approach. Moreover, the human adenocarcinoma cell line of MKN45 was transfected with siRNA against HER-3 and the effects of its down-regulation were evaluated using MTT assay and cell-cycle analysis.

Results: The data obtained from this study revealed HER-3 is significantly overexpressed in gastric tumors rather than non-tumor marginal tissues. Also, it was found that the expression level of HER-3 is elevated with tumor depth of invasion. Moreover, HER-3 knocking down promotes cell accumulation in G2/M phase of cell cycle and decreases cell viability in MKN45 cells which suggests a potential role for HER-3 in gastric adenocarcinoma tumorigenesis.

Conclusion: Taken together, these results emphasize the importance of HER-3 receptor in diagnosis and prognosis of gastric adenocarcinoma.

Citing Articles

Hippo signaling and histone methylation control cardiomyocyte cell cycle re-entry through distinct transcriptional pathways.

Zhang Z, Freeman M, Zhang Y, El-Nachef D, Davenport G, Williams A PLoS One. 2023; 18(2):e0281610.

PMID: 36780463 PMC: 9925018. DOI: 10.1371/journal.pone.0281610.

References

Klapper L, Kirschbaum M, Sela M, Yarden Y . Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 1999; 77:25-79. View

Xia W, Lau Y, Zhang H, Xiao F, Johnston D, Liu A . Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res. 2000; 5(12):4164-74. View

Hubbard S, Till J . Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000; 69:373-98. DOI: 10.1146/annurev.biochem.69.1.373. View

Mendelsohn J, Baselga J . The EGF receptor family as targets for cancer therapy. Oncogene. 2001; 19(56):6550-65. DOI: 10.1038/sj.onc.1204082. View

Citri A, Skaria K, Yarden Y . The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003; 284(1):54-65. DOI: 10.1016/s0014-4827(02)00101-5. View

Holbro T, Civenni G, Hynes N . The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003; 284(1):99-110. DOI: 10.1016/s0014-4827(02)00099-x. View

Atalay G, Cardoso F, Awada A, Piccart M . Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol. 2003; 14(9):1346-63. DOI: 10.1093/annonc/mdg365. View

Osaki M, Oshimura M, Ito H . PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004; 9(6):667-76. DOI: 10.1023/B:APPT.0000045801.15585.dd. View

Jeong E, Soung Y, Lee J, Lee S, Nam S, Lee J . ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer. 2006; 119(12):2986-7. DOI: 10.1002/ijc.22257. View

10.

Hsieh A, Moasser M . Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007; 97(4):453-7. PMC: 2360352. DOI: 10.1038/sj.bjc.6603910. View

11.

Sithanandam G, Anderson L . The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008; 15(7):413-48. PMC: 2761714. DOI: 10.1038/cgt.2008.15. View

12.

Stern D . ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13(2):215-23. PMC: 6590701. DOI: 10.1007/s10911-008-9083-7. View

13.

Koutras A, Fountzilas G, Kalogeras K, Starakis I, Iconomou G, Kalofonos H . The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol. 2009; 74(2):73-8. DOI: 10.1016/j.critrevonc.2009.04.011. View

14.

Center M, Jemal A, Ward E . International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009; 18(6):1688-94. DOI: 10.1158/1055-9965.EPI-09-0090. View

15.

Amin D, Sergina N, Ahuja D, McMahon M, Blair J, Wang D . Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010; 2(16):16ra7. PMC: 3033659. DOI: 10.1126/scitranslmed.3000389. View

16.

Zhang Y, Gonzalez R, Zangar R . Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression. BMC Cancer. 2011; 11:69. PMC: 3050851. DOI: 10.1186/1471-2407-11-69. View

17.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

18.

Jathal M, Chen L, Mudryj M, Ghosh P . Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem. 2011; 11(2):131-149. PMC: 3095967. DOI: 10.2174/187152211795495643. View

19.

Seruga B, Tannock I . Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol. 2011; 29(27):3686-94. DOI: 10.1200/JCO.2010.34.3996. View

20.

Wang K, Kan J, Yuen S, Shi S, Chu K, Law S . Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011; 43(12):1219-23. DOI: 10.1038/ng.982. View